Hospital
Galencare, INC.
Galencare, INC. was paid $34.68M by Medicaid between Jan 2018 and Dec 2024, across 233 billing codes. Its largest line is 99283, emergency room visit (moderate) — 40% of everything it billed.
33Billing provider infoGALENCARE, INC.
BRANDON, FL 33511
BRANDON, FL 33511
33aNPI1669427258assigned 05/23/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$34.68M
24GClaims1,166,333
24DCodes billed233
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Florida
Rank by total paid#5 of 163
Median peer was paid$4.77M
This provider vs. median7.3×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 64,971 | $747K | |
| 2019 | 198,820 | $2.92M | |
| 2020 | 168,730 | $2.73M | |
| 2021 | 217,988 | $6.22M | |
| 2022 | 253,689 | $9.49M | |
| 2023 | 168,481 | $7.77M | |
| 2024incomplete | 93,654 | $4.80M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 40% | 143,541 | 132,449 | $13.80M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 13% | 70,667 | 61,398 | $4.51M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 9.4% | 33,724 | 31,953 | $3.25M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 4.5% | 7,959 | 7,148 | $1.57M |
| 80053 | Comprehensive metabolic panel | 4.0% | 61,060 | 51,074 | $1.39M |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 3.0% | 10,271 | 9,593 | $1.05M |
| 70450 | Computed tomography, head or brain; without contrast material | 2.7% | 8,660 | 7,373 | $929K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 2.3% | 10,754 | 9,075 | $783K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.7% | 4,343 | 3,832 | $575K |
| 71275 | Computed tomographic angiography, chest, with contrast material | 1.4% | 2,491 | 2,179 | $472K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 1.1% | 16,461 | 15,589 | $396K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 5,492 | 5,041 | $308K |
221 more codes
| 87070 | <1% | 22,441 | $245K | |
| 87400 | <1% | 38,658 | $217K | |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 2,845 | $191K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 4,424 | $174K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 3,202 | $174K |
| 76830 | Ultrasound, transvaginal | <1% | 2,429 | $162K |
| 58670 | <1% | 189 | $155K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 3,109 | $147K |
| G0378 | Hospital observation service, per hour | <1% | 12,223 | $134K |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 3,716 | $129K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 1,873 | $122K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 2,705 | $122K |
| 59025 | Fetal non-stress test | <1% | 1,056 | $119K |
| 76801 | <1% | 2,572 | $118K | |
| 81025 | <1% | 24,015 | $118K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 5,287 | $118K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 19,574 | $102K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 1,547 | $100K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 2,563 | $98K |
| 93975 | <1% | 5,627 | $98K | |
| 81001 | <1% | 28,121 | $96K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 8,109 | $89K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 1,540 | $84K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 2,330 | $83K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 16,098 | $77K |
| J3490 | Unclassified drugs | <1% | 1,654 | $76K |
| 12011 | <1% | 1,106 | $70K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 3,614 | $70K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 5,973 | $70K |
| 71045 | Radiologic examination, chest; single view | <1% | 18,227 | $69K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 2,236 | $68K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 7,842 | $67K |
| 12001 | <1% | 1,174 | $66K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 1,223 | $63K |
| 86850 | <1% | 3,139 | $61K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 2,437 | $60K |
| 93971 | <1% | 1,355 | $52K | |
| 85027 | <1% | 69,006 | $51K | |
| 10060 | <1% | 926 | $49K | |
| 74018 | <1% | 2,949 | $49K | |
| 87210 | <1% | 5,471 | $49K | |
| 72131 | <1% | 963 | $48K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 804 | $43K |
| 81003 | <1% | 9,252 | $43K | |
| 73130 | <1% | 2,492 | $42K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 970 | $41K |
| 93970 | <1% | 641 | $38K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 34,597 | $37K |
| 84702 | <1% | 6,320 | $35K | |
| 87430 | <1% | 26,495 | $33K | |
| 84112 | <1% | 749 | $33K | |
| 87420 | <1% | 7,435 | $33K | |
| A9270 | Non-covered item or service | <1% | 15,278 | $32K |
| 73630 | <1% | 3,222 | $31K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 22,404 | $30K |
| 73610 | <1% | 2,843 | $30K | |
| 84484 | <1% | 18,602 | $29K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 21,699 | $28K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 16,815 | $27K |
| 73140 | <1% | 976 | $27K | |
| 73564 | <1% | 2,833 | $27K | |
| 73030 | <1% | 1,983 | $26K | |
| 70491 | <1% | 110 | $26K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 248 | $25K |
| 73110 | <1% | 1,730 | $24K | |
| 70486 | <1% | 526 | $21K | |
| G0383 | Level 4 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | <1% | 150 | $21K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 600 | $20K |
| 87040 | <1% | 5,275 | $19K | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 10,520 | $19K |
| 12002 | <1% | 431 | $18K | |
| J2916 | Injection, sodium ferric gluconate complex in sucrose injection, 12.5 mg | <1% | 361 | $18K |
| 76770 | <1% | 135 | $17K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 12,816 | $17K |
| 96376 | <1% | 4,571 | $17K | |
| 72110 | <1% | 552 | $17K | |
| 73090 | <1% | 926 | $17K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 191 | $15K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 7,193 | $15K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,860 | $14K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 2,087 | $13K |
| J2704 | Injection, propofol, 10 mg | <1% | 1,274 | $13K |
| 86900 | <1% | 5,360 | $12K | |
| 84703 | <1% | 13,481 | $12K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 4,352 | $12K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 1,477 | $12K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 6,859 | $12K |
| 83880 | <1% | 4,831 | $11K | |
| 85610 | <1% | 9,143 | $10K | |
| 73070 | <1% | 651 | $10K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 293 | $8K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 12,693 | $8K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 3,938 | $8K |
| 85730 | <1% | 7,135 | $8K | |
| 71101 | <1% | 166 | $8K | |
| C1729 | Catheter, drainage | <1% | 224 | $7K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 7,111 | $7K |
| 73590 | <1% | 965 | $7K | |
| 83735 | <1% | 11,913 | $7K | |
| 83605 | <1% | 4,237 | $7K | |
| 81002 | <1% | 8,677 | $6K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 76 | $6K |
| 76820 | <1% | 1,428 | $5K | |
| 95816 | <1% | 134 | $5K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 1,036 | $5K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 4,356 | $5K |
| 86901 | <1% | 5,352 | $5K | |
| 76857 | <1% | 380 | $5K | |
| S0028 | Injection, famotidine, 20 mg | <1% | 3,285 | $5K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 27 | $4K |
| 93017 | <1% | 220 | $4K | |
| J1815 | Injection, insulin, per 5 units | <1% | 2,183 | $4K |
| 97163 | <1% | 422 | $4K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 4,454 | $4K |
| 85379 | <1% | 3,789 | $3K | |
| 72128 | <1% | 57 | $3K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 3,462 | $3K |
| 87186 | <1% | 3,291 | $3K | |
| 84145 | <1% | 888 | $3K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 114 | $2K |
| 73080 | <1% | 134 | $2K | |
| 83690 | <1% | 15,008 | $2K | |
| C1769 | Guide wire | <1% | 111 | $2K |
| 80061 | Lipid panel | <1% | 1,660 | $2K |
| 29125 | <1% | 677 | $2K | |
| 70487 | <1% | 12 | $2K | |
| 36430 | <1% | 27 | $2K | |
| 73502 | <1% | 271 | $2K | |
| 88307 | <1% | 31 | $2K | |
| 80069 | <1% | 653 | $2K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,237 | $2K |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 2,772 | $2K |
| 86140 | <1% | 2,398 | $2K | |
| 86738 | <1% | 745 | $2K | |
| 00840 | <1% | 66 | $1K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 217 | $1K |
| 76870 | <1% | 146 | $1K | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 32 | $1K |
| 88304 | <1% | 143 | $1K | |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 220 | $1K |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 1,475 | $1K |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,194 | $1K |
| 76818 | <1% | 15 | $1K | |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 418 | $1K |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 508 | $1K |
| 87205 | <1% | 1,552 | $962.02 | |
| 29515 | <1% | 115 | $911.07 | |
| 73060 | <1% | 165 | $884.66 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 2,979 | $874.16 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 2,323 | $857.40 |
| 82270 | <1% | 59 | $853.07 | |
| Q0244 | Injection, casirivimab and imdevimab, 1200 mg | <1% | 14 | $850.61 |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 27 | $844.37 |
| 12013 | <1% | 12 | $836.08 | |
| 96368 | <1% | 13 | $834.79 | |
| 82570 | <1% | 528 | $745.54 | |
| 82731 | <1% | 12 | $742.73 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 4,720 | $731.92 |
| 73660 | <1% | 79 | $672.83 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 2,748 | $660.21 |
| 82550 | <1% | 1,635 | $595.69 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 1,329 | $556.50 |
| 82247 | <1% | 30 | $494.81 | |
| 99152 | <1% | 17 | $489.36 | |
| 73503 | <1% | 28 | $483.60 | |
| 84439 | <1% | 996 | $470.32 | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 15 | $465.48 |
| 85652 | <1% | 778 | $448.62 | |
| 73100 | <1% | 16 | $410.00 | |
| 86308 | <1% | 154 | $403.48 | |
| 84156 | <1% | 603 | $393.78 | |
| 84100 | <1% | 659 | $380.30 | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 202 | $360.92 |
| J2791 | Injection, rho(d) immune globulin (human), (rhophylac), intramuscular or intravenous, 100 iu | <1% | 41 | $327.52 |
| 90714 | <1% | 885 | $316.62 | |
| 85045 | <1% | 293 | $296.35 | |
| 86592 | <1% | 68 | $293.53 | |
| 71250 | <1% | 13 | $287.52 | |
| 85384 | <1% | 105 | $278.65 | |
| 72100 | <1% | 27 | $237.25 | |
| 73552 | <1% | 133 | $212.52 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 125 | $210.42 |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 127 | $168.10 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 205 | $160.04 |
| 74019 | <1% | 102 | $143.30 | |
| 93880 | <1% | 22 | $137.51 | |
| 97116 | <1% | 25 | $130.19 | |
| 82803 | <1% | 120 | $128.29 | |
| G1003 | Clinical decision support mechanism medicalis, as defined by the medicare appropriate use criteria program | <1% | 456 | $120.14 |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 37 | $116.20 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 158 | $75.88 |
| 90715 | <1% | 540 | $73.52 | |
| J0500 | Injection, dicyclomine hcl, up to 20 mg | <1% | 138 | $45.53 |
| 70360 | <1% | 27 | $35.85 | |
| 76821 | <1% | 15 | $31.07 | |
| 80076 | <1% | 58 | $16.66 | |
| 82248 | <1% | 84 | $11.76 | |
| 83615 | <1% | 197 | $1.47 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | 0% | 417 | $0.00 |
| C1758 | Catheter, ureteral | 0% | 83 | $0.00 |
| S0077 | Injection, clindamycin phosphate, 300 mg | 0% | 116 | $0.00 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 0% | 274 | $0.00 |
| 00851 | 0% | 202 | $0.00 | |
| J3370 | Injection, vancomycin hcl, 500 mg | 0% | 208 | $0.00 |
| Q0177 | Hydroxyzine pamoate, 25 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 0% | 177 | $0.00 |
| 84550 | 0% | 96 | $0.00 | |
| S5000 | Prescription drug, generic | 0% | 48 | $0.00 |
| 85014 | 0% | 14 | $0.00 | |
| 76827 | 0% | 25 | $0.00 | |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 43 | $0.00 |
| J0456 | Injection, azithromycin, 500 mg | 0% | 126 | $0.00 |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | 0% | 658 | $0.00 |
| 88342 | 0% | 207 | $0.00 | |
| J1630 | Injection, haloperidol, up to 5 mg | 0% | 58 | $0.00 |
| 73560 | 0% | 13 | $0.00 | |
| 82150 | 0% | 59 | $0.00 | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | 0% | 25 | $0.00 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | 0% | 26 | $0.00 |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | 0% | 37 | $0.00 |
| 76825 | 0% | 25 | $0.00 | |
| J1940 | Injection, furosemide, up to 20 mg | 0% | 20 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialKING, MATTHEW (CFO)
| Provider | Location | Paid |
|---|---|---|
| Anova Medical Associates, PLC | Gallatin, TN | $862K |
| Sodus Town Ambulance Corps | North Rose, NY | $233K |
| Town Line Eye Care, LLC | Rocky Hill, CT | $80K |
| Fannin County Hospital Authority | Bedford, TX | $0.00 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.